Navigation Links
Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Date:10/21/2010

NEW YORK, Oct. 21 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

http://www.reportlinker.com/p0316116/Commercializing-Cancer-Vaccines-A-Decision-Support-Tool-for-Optimizing-the-Pipeline.html

This report comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. The report extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the cancer vaccine pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of cancer vaccine drugs is split between the 46% which have unique drug target strategies and the other half which have head-to-head target competing vaccine drugs in 20 different clusters. The latter has a competing ratio which is almost two and half time higher than the comparable average of cancer vaccine drugs. Contributing to this fact is heavily utilized drug target strategies like: ERBB2, TERT and MUC1.

* Nine out of ten drug target strategies in Phase III development are new to cancer vaccine drugs, whereas the greatest number of new target strategies are found in Preclinical- and Phase II development.

* Protein and gene therapy are the dominating compound strategies of cancer vaccine drugs, which represent half of the entire pipeline. Cell therapy based cancer vaccines has the least unique target strategy portfolio compared to that of other compound strategies of cancer vaccine drugs.

* The highest numbers of described target strategies among cancer vaccine drugs are found in breast cancer, colorectal cancer, melanoma and prostate cancer. Cancer vaccine drugs are experiencing targeting competition in one out of every three cancer indications described, and more so in cervical cancer/dysplasia, prostate cancer, head and neck cancer and breast cancer.

* The highest number of described drug target strategies of cancer vaccine drugs belongs to Advaxis, Cancer Research Technology, Dendreon and Inovio. However, when looking at the highest number of developmental projects Celldex Therapeutics, Cell Genesys, Advaxis and Dendreon take the lead.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any cancer vaccine drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3

2 About Cancer Highlights™ 5

2.1 Cancer Focus Areas 5

2.2 Subscribe Today and Start Saving 6

2.2.1 Type of License 6

2.3 BioSeeker Group's Oncology Team 6

3 Methodology 7

3.1 Cancer Highlights'™ Five Pillar Drug Assessment 7

4 Table of Contents 9

4.1 List of Figures 18

4.2 List of Tables 18

5 Introduction 26

5.1 The Scope of this Report 26

5.2 Definitions 29

5.3 Abbreviations 29

6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment 30

6.1 Drug Repositioning in Oncology 30

6.2 Introduction to Targets of Cancer Vaccine Drugs 31

6.2.1 Acid Phosphatase Activity Targets 35

6.2.2 Carboxypeptidase Activity Targets 36

6.2.3 Catalytic Activity Targets 38

6.2.4 Cell Adhesion Molecule Activity Targets 40

6.2.5 Chaperone Activity Targets 44

6.2.6 Cofactor Binding Targets 45

6.2.7 Complement Activity Targets 47

6.2.8 Cytokine Activity Targets 49

6.2.9 DNA Binding Targets 58

6.2.10 DNA Topoisomerase Activity Targets 60

6.2.11 DNA-directed DNA Polymerase Activity Targets 61

6.2.12 Growth Factor Activity Targets 62

6.2.13 Heat Shock Protein Activity Targets 69

6.2.14 Hormone Activity Targets 70

6.2.15 Isomerase Activity Targets 71

6.2.16 Kinase Binding Targets 72

6.2.17 Kinase Regulator Activity Targets 74

6.2.18 Metallopeptidase Activity Targets 76

6.2.19 MHC Class I Receptor Activity Targets 78

6.2.20 Molecular Function Unknown Targets 79

6.2.21 Oxidoreductase Activity Targets 91

6.2.22 Peptidase Activity Targets 93

6.2.23 Peptide Hormone Targets 101

6.2.24 Protein Binding Targets 104

6.2.25 Protein Serine/Threonine Kinase Activity Targets 106

6.2.26 Protein-tyrosine Kinase Activity Targets 109

6.2.27 Receptor Activity Targets 111

6.2.28 Receptor Signaling Complex Scaffold Activity Targets 119

6.2.29 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 121

6.2.30 RNA-directed DNA Polymerase Activity Targets 122

6.2.31 Serine-type Peptidase Activity Targets 124

6.2.32 T Cell Receptor Activity Targets 127

6.2.33 Transcription Factor Activity Targets 128

6.2.34 Transcription Regulator Activity Targets 133

6.2.35 Transmembrane Receptor Activity Targets 134

6.2.36 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 135

6.2.37 Transporter Activity Targets 147

6.2.38 Other Targets 150

6.3 The Cancer Genome Project and Targets of Cancer Vaccine Drugs 157

6.3.1 Targets of Cancer Vaccine Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 157

6.4 Structure-based Drug Design in Cancer Vaccine Therapeutics is Stimulated by Available Structure Data on Biological Targets 161

6.5 Target-Target Interactions among Identified Targets of Cancer Vaccine Drugs 163

6.6 The Drug-Target Competitive Landscape 166

6.7 Protein Expression Levels of Identified Targets of Cancer Vaccine Drugs 170

6.8 Pathway Assessment of Caner Vaccine Drugs 173

6.8.1 Tools for Analysis of Cancer Pathways 174

6.8.2 Pathway Assessment 175

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development 195

7.1 Marketed: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 197

7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 197

7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 198

7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 200

7.5 Preclinical Development: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 202

7.6 No Development Data: New and Unique Drug Target Strategies of Cancer Vaccine Drugs 204

7.7 Drug Target Strategies of Suspended, Discontinued or Terminated Cancer Vaccine Drugs 205

7.8 Target Strategy Profiles of Cancer Vaccine Drugs 208

7.8.1 Marketed 211

7.8.2 Phase III 212

7.8.3 Phase II 223

7.8.4 Phase I 244

7.8.5 Preclinical 255

7.8.6 Suspended 275

7.8.7 Ceased 276

7.9 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 306

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy 309

8.1 Small Molecules 311

8.1.1 Background 311

8.1.2 Target Strategies of Small Molecule Drugs 312

8.2 Peptide & Protein Drugs 314

8.2.1 Background 314

8.2.2 Target Strategies of Peptide and Protein Drugs 315

8.3 Antibodies and Antibody-like Structures 321

8.3.1 Background 321

8.3.2 Target Strategies of Antibody Drugs 321

8.4 Nucleic Acid Therapies 324

8.4.1 Background 324

8.4.2 Target Strategies of Nucleic Acid Drugs 325

8.5 Cell & Gene Therapy 327

8.5.1 Background 327

8.5.2 Target Strategies of Cell and Gene Therapy Drugs 328

8.6 Compound Strategies based on Sub-Cellular Localization of Drug Targets 334

9 Selecting Cancer Indications for Cancer Vaccine Drugs 339

9.1 Acute Lymphocytic Leukemia 342

9.2 Acute Myelogenous Leukemia 343

9.3 Anal Dysplasia 344

9.4 B-cell Lymphoma 344

9.5 Bladder Cancer 345

9.6 Bone Cancer 346

9.7 Brain Cancer 346

9.8 Breast Cancer 347

9.9 Cancer (general) 349

9.10 Cervical Cancer 350

9.11 Chemotherapy-induced Bone Marrow Injury (general) 351

9.12 Cervical Dysplasia 352

9.13 Chronic Myelogenous Leukemia 353

9.14 Colorectal Cancer 354

9.15 Gastrointestinal Cancer (general) 356

9.16 Gastrointestinal Stomach Cancer 356

9.17 Head and Neck Cancer 357

9.18 Hematological Cancer (general) 358

9.19 Leukemia (general) 358

9.20 Liver Cancer 359

9.21 Lung Cancer (general) 360

9.22 Lymphoma (general) 361

9.23 Melanoma 362

9.24 Mesothelioma 364

9.25 Myelodysplastic Syndrome 364

9.26 Myeloma 365

9.27 non-Hodgkin's Lymphoma 366

9.28 Non-Small Cell Lung Cancer 367

9.29 Oesophageal Cancer 369

9.30 Osteo Sarcoma 370

9.31 Ovarian Cancer 371

9.32 Pancreatic Cancer 374

9.33 Prostate Cancer 376

9.34 Renal Cancer 379

9.35 Skin Cancer (general) 381

9.36 Small Cell Lung Cancer 381

9.37 Soft Tissue Sarcoma 381

9.38 Solid Tumor 381

9.39 Squamous Cell Cancer 382

9.40 Thyroid Cancer 382

9.41 Unspecified Cancer Indication 383

9.42 Vaccine adjunct 386

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator 387

10.1 Competitive Fall-Out Assessment 387

10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 389

10.3 AC Immune 390

10.4 Adaptimmune 392

10.5 Aduro BioTech 395

10.6 Advaxis 397

10.7 Aida Pharmaceuticals 402

10.8 Akela Pharma 404

10.9 AlphaVax 407

10.10 Apthera 410

10.11 Astellas 413

10.12 AstraZeneca 415

10.13 AVI BioPharma 418

10.14 Bavarian Nordic 421

10.15 Bellicum Pharmaceuticals 426

10.16 Biogen Idec 428

10.17 Biostar 430

10.18 BioVex 432

10.19 Cadila 434

10.20 Cancer Research Technology 436

10.21 Cell Genesys 441

10.22 Celldex Therapeutics 445

10.23 CG Therapeutics 449

10.24 Cosmo Pharmaceuticals 452

10.25 CSL 455

10.26 Dendreon 457

10.27 DeveloGen 463

10.28 Eisai 465

10.29 Eli Lilly 467

10.30 EntreMed 469

10.31 Epeius Biotechnologies 471

10.32 Generex 473

10.33 GenOdyssee Pharmaceuticals 476

10.34 GENTICEL 478

10.35 Geron 480

10.36 GlaxoSmithKline 484

10.37 Gliknik 488

10.38 GlobeImmune 490

10.39 Gradalis 493

10.40 Ichor Medical Systems 495

10.41 Idera Pharmaceuticals 497

10.42 ImmunoCellular Therapeutics 500

10.43 ImmunoFrontier 502

10.44 Immunotope 506

10.45 Innate Pharma 508

10.46 Inovio 510

10.47 Introgen Therapeutics 515

10.48 ISA Pharmaceuticals 517

10.49 Johnson & Johnson 519

10.50 Medical Marketing International 521

10.51 MediGene 524

10.52 Menarini 527

10.53 Merck KGaA 530

10.54 Micromet 532

10.55 MolMed 534

10.56 Mologen 536

10.57 Nemod Biotherapeutics 539

10.58 Neovacs 542

10.59 NIH – US National Institute of Health 545

10.60 Non-industrial Sources 548

10.61 Northwest Biotherapeutics 554

10.62 NovaRx 556

10.63 OncoMune 559

10.64 OncoTherapy Science 561

10.65 Oncothyreon 563

10.66 Oncovir 567

10.67 Onyvax 569

10.68 Oxford BioMedica 571

10.69 Pepscan Systems 574

10.70 Pepscan Therapeutics 577

10.71 Pfizer 580

10.72 Pharmexa 582

10.73 Prima Biomed 587

10.74 Progenics Pharmaceuticals 590

10.75 Protherics 593

10.76 Radient Pharmaceuticals 595

10.77 Receptor BioLogix 597

10.78 responsif 600

10.79 Sanofi-Aventis 602

10.80 Scancell 604

10.81 SciClone Pharmaceuticals 607

10.82 TapImmune 609

10.83 Therion Biologics 611

10.84 Transgene 618

10.85 United Biomedical 622

10.86 Vaccinex 624

10.87 Vaxil BioTherapeutics 627

10.88 Vaxon Biotech 630

10.89 VaxOnco 633

10.90 Vectura 636

10.91 Vical 638

10.92 Viragen 641

10.93 Virionics 643

10.94 ViroMed 645

10.95 Zensun 648

11 Disclaimer 650

12 Drug Index 651

13 Company Index 656

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Cancer Vaccine Drugs 165

Figure 2: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Large Cluster 167

Figure 3: The Drug-Target Competitive Landscape of Cancer Vaccine Drugs - Smaller Clusters 168

Figure 4: Head-to-Head Targeting Competitive Landscape of Cancer Vaccine Drugs 169

Figure 5: Distribution of Compound Strategies among Cancer Vaccine Drugs 334

Figure 6: Primary Sub-cellular Localization of Drug Targets 335

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7

Table 2: Breakdown of the Included Cancer Vaccine Drug Pipeline by Stage of Development 26

Table 3: Head to Head Target Competition among Cancer Vaccine Drugs 26

Table 4: Overview of Drug Target Strategy Themes 31

Table 5: Terminally Ceased Targets of Cancer Vaccine Drugs 32

Table 6: Official Gene Name to Target Profle 33

Table 7: Targets of Cancer Vaccine Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 158

Table 8: Identity of Cancer Vaccine Drug Targets with Available Biological Structures 161

Table 9: Number of Target-Target Interactions among Targets of Cancer Vaccine Drugs 163

Table 10: Available Protein Expression Profiles of Cancer Vaccine Drugs Targets 170

Table 11: Pathway Summary 175

Table 12: Drug Targets without any Identified Assigned Pathways 175

Table 13: Pathway Profiles According to BioCarta of Cancer Vaccine Drug Targets 177

Table 14: Pathway Profiles According to KEGG of Cancer Vaccine Drug Targets 184

Table 15: Pathway Profiles According to NetPath of Cancer Vaccine Drug Targets 193

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 195

Table 17: Top Competitive Target Strategies of Cancer Vaccine Drugs 196

Table 18: New and Unique Target Strategies of Marketed Cancer Vaccine Drugs 197

Table 19: New and Unique Target Strategies in Phase III Clinical Development of Cancer Vaccine Drugs 197

Table 20: New and Unique Target Strategies in Phase II Clinical Development of Cancer Vaccine Drugs 198

Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Vaccine Drugs 199

Table 22: New and Unique Target Strategies in Phase I Clinical Development of Cancer Vaccine Drugs 200

Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Vaccine Drugs 201

Table 24: New and Unique Target Strategies in Preclinical Development of Cancer Vaccine Drugs 202

Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Vaccine Drugs 203

Table 26: New and Unique Target Strategies in Unknown Developmental Stage of Cancer Vaccine Drugs 204

Table 27: The Competition Through Close Mechanistic Approximation Between Cancer Vaccine Drugs with No Developmental Data 204

Table 28: Target Strategies of Suspended, Discontinued and Terminated Cancer Vaccine Drugs 206

Table 29: Connecting Target Strategy with Its Identification Number 208

Table 30: The Competition Through Close Mechanistic Approximation Among Cancer Vaccine Drugs 306

Table 31: Overview of Compound Strategy Competition Among Cancer Vaccine Drugs 310

Table 32: Overview of the Competitive Landscape of Small Molecule Based Cancer Vaccines Drugs 312

Table 33: Pursued Target Strategies of Small Molecule Drugs Based Cancer Vaccines Drugs 313

Table 34: Overview of the Competitive Landscape of Peptide Based Cancer Vaccines Drugs 315

Table 35: Competitive Comparison of Target Strategies of Peptide Based Cancer Vaccines Drugs 316

Table 36: Pursued Target Strategies of Peptide Based Cancer Vaccines Drugs 316

Table 37: Overview of the Competitive Landscape of Protein Based Cancer Vaccines Drugs 318

Table 38: Competitive Comparison of Target Strategies of Protein Based Cancer Vaccines Drugs 319

Table 39: Pursued Target Strategies of Protein Based Cancer Vaccines Drugs 319

Table 40: Overview of the Competitive Landscape of Antibody Based Cancer Vaccines Drugs 321

Table 41: Competitive Comparison of Target Strategies of Antibody Based Cancer Vaccines Drugs 322

Table 42: Pursued Target Strategies of Antibody Based Cancer Vaccines Drugs 322

Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Cancer Vaccines Drugs 325

Table 44: Pursued Target Strategies of Nucleic Acid Based Cancer Vaccines Drugs 326

Table 45: Potential Forms of Cell Therapy 327

Table 46: Vectors in Gene Therapy 328

Table 47: Overview of the Competitive Landscape of Cell Therapy Based Cancer Vaccines Drugs 328

Table 48: Competitive Comparison of Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 329

Table 49: Pursued Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 329

Table 50: Overview of the Competitive Landscape of Gene Therapy Based Cancer Vaccines Drugs 330

Table 51: Competitive Comparison of Target Strategies of Gene Therapy Based Cancer Vaccines Drugs 331

Table 52: Pursued Target Strategies of Gene Therapy Based Cancer Vaccines Drugs 332

Table 53: Compound Strategies based on Sub-Cellular Localization of Cancer Vaccine Drug Targets 335

Table 54 Competitive Summary by Cancer Indication of Cancer Vaccine Drugs 340

Table 55: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Lymphocytic Leukemia 342

Table 56: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Myelogenous Leukemia 343

Table 57: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Anal Dysplasia 344

Table 58: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of B-cell Lymphoma 344

Table 59: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bladder Cancer 345

Table 60: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bone Cancer 346

Table 61: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Brain Cancer 346

Table 62: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Breast Cancer 347

Table 63: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 348

Table 64: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cancer (general) 349

Table 65: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Cancer 350

Table 66: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 351

Table 67: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chemotherapy-induced Bone Marrow Injury (general) 351

Table 68: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Dysplasia 352

Table 69: The Competition through Close Mechanistic Approximation between Cervical Dysplasia Drugs 353

Table 70: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chronic Myelogenous Leukemia 353

Table 71: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Cancer 354

Table 72: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 355

Table 73: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Cancer (general) 356

Table 74: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Stomach Cancer 356

Table 75: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Head and Neck Cancer 357

Table 76: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 357

Table 77: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Hematological Cancer (general) 358

Table 78: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Leukemia (general) 358

Table 79: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Liver Cancer 359

Table 80: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 359

Table 81: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lung Cancer (general) 360

Table 82: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 361

Table 83: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lymphoma (general) 361

Table 84: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Melanoma 362

Table 85: The Competition through Close Mechanistic Approximation between Melanoma Drugs 363

Table 86: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Mesothelioma 364

Table 87: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myelodysplastic Syndrome 364

Table 88: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myeloma 365

Table 89: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of non-Hodgkin's Lymphoma 366

Table 90: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer 367

Table 91: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 368

Table 92: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Oesophageal Cancer 369

Table 93: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Osteo Sarcoma 370

Table 94: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Ovarian Cancer 371

Table 95: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 373

Table 96: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Pancreatic Cancer 374

Table 97: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 375

Table 98: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Prostate Cancer 376

Table 99: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 377

Table 100: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Renal Cancer 379

Table 101: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 380

Table 102: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Skin Cancer (general) 381

Table 103: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Small Cell Lung Cancer 381

Table 104: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Soft Tissue Sarcoma 381

Table 105: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Solid Tumor 381

Table 106: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Squamous Cell Cancer 382

Table 107: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Thyroid Cancer 382

Table 108: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Unspecified Cancer Indication 383

Table 109: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 384

Table 110: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Vaccine adjunct 386

Table 111: Example of a Competitive Fall-Out Table (Modified, Platelet glycoprotein 4 trageting drugs) 388

Table 112: Summary Table of Corporate Changes in the Competitive Landscape of Cancer Vaccine Drug Development 389

Table 113: AC Immune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 390

Table 114: Adaptimmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 392

Table 115: Aduro BioTech's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 395

Table 116: Advaxis' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 397

Table 117: Aida Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 402

Table 118: Akela Pharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 404

Table 119: AlphaVax's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 407

Table 120: Apthera's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 410

Table 121: Astellas' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 413

Table 122: AstraZeneca's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 415

Table 123: AVI BioPharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 418

Table 124: Bavarian Nordic's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 421

Table 125: Bellicum Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 426

Table 126: Biogen Idec's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 428

Table 127: Biostar's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 430

Table 128: BioVex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 432

Table 129: Cadila's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 434

Table 130: Cancer Research Technology's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 436

Table 131: Cell Genesys' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 441

Table 132: Celldex Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 445

Table 133: CG Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 449

Table 134: Cosmo Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 452

Table 135: CSL's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 455

Table 136: Dendreon's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 457

Table 137: DeveloGen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 463

Table 138: Eisai's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 465

Table 139: Eli Lilly's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 467

Table 140: EntreMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 469

Table 141: Epeius Biotechnologies' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 471

Table 142: Generex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 473

Table 143: GenOdyssee Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 476

Table 144: GENTICEL's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 478

Table 145: Geron's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 480

Table 146: GlaxoSmithKline's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 484

Table 147: Gliknik's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 488

Table 148: GlobeImmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 490

Table 149: Gradalis' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 493

Table 150: Ichor Medical Systems' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 495

Table 151: Idera Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 497

Table 152: ImmunoCellular Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 500

Table 153: ImmunoFrontier's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 502

Table 154: Immunotope's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 506

Table 155: Innate Pharma's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 508

Table 156: Inovio's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 510

Table 157: Introgen Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 515

Table 158: ISA Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 517

Table 159: Johnson & Johnson's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 519

Table 160: Medical Marketing International's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 521

Table 161: MediGene's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 524

Table 162: Menarini's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 527

Table 163: Merck KGaA's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 530

Table 164: Micromet's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 532

Table 165: MolMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 534

Table 166: Mologen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 536

Table 167: Nemod Biotherapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 539

Table 168: Neovacs' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 542

Table 169: NIH's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 545

Table 170: Non-industrial Sources' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 548

Table 171: Northwest Biotherapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 554

Table 172: NovaRx's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 556

Table 173: OncoMune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 559

Table 174: OncoTherapy Science's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 561

Table 175: Oncothyreon's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 563

Table 176: Oncovir's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 567

Table 177: Onyvax's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 569

Table 178: Oxford BioMedica's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 571

Table 179: Pepscan Systems' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 574

Table 180: Pepscan Therapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 577

Table 181: Pfizer's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 580

Table 182: Pharmexa's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 582

Table 183: Prima Biomed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 587

Table 184: Progenics Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 590

Table 185: Protherics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 593

Table 186: Radient Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 595

Table 187: Receptor BioLogix's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 597

Table 188: responsif's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 600

Table 189: Sanofi-Aventis' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 602

Table 190: Scancell's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 604

Table 191: SciClone Pharmaceuticals' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 607

Table 192: TapImmune's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 609

Table 193: Therion Biologics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 611

Table 194: Transgene's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 618

Table 195: United Biomedical's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 622

Table 196: Vaccinex's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 624

Table 197: Vaxil BioTherapeutics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 627

Table 198: Vaxon Biotech's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 630

Table 199: VaxOnco's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 633

Table 200: Vectura's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 636

Table 201: Vical's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 638

Table 202: Viragen's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 641

Table 203: Virionics' Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 643

Table 204: ViroMed's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 645

Table 205: Zensun's Included Cancer Vaccine Drug Pipeline and Competitive Fall-Out 648

To order this report:Drug Discovery and Development Industry: Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):